Ib J. Christensen

Herlev, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 200 publications

Molecular Sub-Classification Suggests IBD Unclassified as a Distinct Subtype of Inflammatory Bowel Disease: Insights From a 3-Gene Mucosal Signature.

Molecular Sub-Classification Suggests IBD Unclassified as a Distinct Subtype of Inflammatory Bowel Disease: Insights From a 3-Gene Mucosal Signature.

Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

Published: June 29, 2026

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Journal: Cancer chemotherapy and pharmacology

Published: March 27, 2026

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients.

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients.

Journal: British journal of clinical pharmacology

Published: September 30, 2025

Identifying targetable alterations predictive of distant progression in glioblastoma patients undergoing standard therapy.

Identifying targetable alterations predictive of distant progression in glioblastoma patients undergoing standard therapy.

Journal: Neuro-oncology advances

Published: June 27, 2025

Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer.

Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 21, 2025

Novel Blood-Based Biomarker Candidates in Screening for Colorectal Cancer.

Novel Blood-Based Biomarker Candidates in Screening for Colorectal Cancer.

Journal: Clinical colorectal cancer

Published: March 27, 2025

Magnetic resonance imaging and o-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic glioma.

Magnetic resonance imaging and o-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic glioma.

Journal: Neuro-oncology advances

Published: December 11, 2024

Circulating Tumor DNA in Addition to Fecal Immunochemical Test in a Dual-Test Colorectal Cancer Screening Approach.

Circulating Tumor DNA in Addition to Fecal Immunochemical Test in a Dual-Test Colorectal Cancer Screening Approach.

Journal: Clinical colorectal cancer

Published: November 13, 2024

TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real-Word Patients With Primary Large B-Cell Lymphoma.

TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real-Word Patients With Primary Large B-Cell Lymphoma.

Journal: European journal of haematology

Published: September 18, 2024

Evaluation of the Oncomine Comprehensive Assay Plus NGS Panel and the OncoScan CNV Assay for Homologous Recombination Deficiency Detection.

Evaluation of the Oncomine Comprehensive Assay Plus NGS Panel and the OncoScan CNV Assay for Homologous Recombination Deficiency Detection.

Journal: Molecular diagnosis & therapy

Published: September 08, 2024

Development of an algorithm combining blood-based biomarkers, fecal immunochemical test, and age for population-based colorectal cancer screening.

Development of an algorithm combining blood-based biomarkers, fecal immunochemical test, and age for population-based colorectal cancer screening.

Journal: Gastrointestinal endoscopy

Published: March 21, 2024

Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study.

Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 03, 2024

Showing 1-12 of 200

Last Updated: 09/26/2026